Contact Us
Drug Search Results
More Filters [+]

Nimotuzumab

Alternative Names: nimotuzumab, h-r3, theracim
Latest Update: 2024-12-10
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: EGFR Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Algeria | Argentina | Brazil | Chile | Colombia | India | Indonesia | Ireland | Philippines | Thailand | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: YM BioSciences
Company Location: MISSISSAUGA A6 00000
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Nimotuzumab

Countries in Clinic: China, Italy

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer|Head and Neck Cancer|Pancreatic Cancer|Squamous Cell Carcinoma

Phase 2: Glioma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
DIPG

P2

Unknown Status

Glioma

2025-10-28

CTR20211826

P3

Completed

Head and Neck Cancer|Squamous Cell Carcinoma

2023-01-19

CTR20131232

P3

Completed

Pancreatic Cancer

2022-01-27

CTR20201137

P2

Not yet recruiting

Glioma

None

Recent News Events

Date

Type

Title

07/11/2024

News Article

 Head and Neck Cancer Treatment Market size is set to grow by USD 7.12 billion from 2024-2028, Increasing incidence of head and neck cancers boost the market, Technavio

04/27/2024

PubMed

 A natural compound melatonin enhances the effects of Nimotuzumab via inhibiting EGFR in glioblastoma.

03/21/2024

PubMed

 Addition of nimotuzumab to concurrent chemoradiotherapy after induction chemotherapy improves outcomes of patients with locally advanced nasopharyngeal carcinoma.

02/15/2024

PubMed

 Efficacy and Safety of Nimotuzumab in Combination with Radiotherapy or Chemoradiotherapy for Local Advanced Head and Neck Cancer: A Systematic Review and Meta-analysis.

06/15/2023

News Article

 Ophthalmic Drugs Market to Reach US$ 70.76 Billion by 2030, Says Coherent Market Insights

04/12/2023

News Article

 Monoclonal Antibody Therapeutics Market to Surpass US$ 534.26 Billion by 2030, Says Coherent Market Insights (CMI)

03/03/2023

News Article

 Allergic Rhinitis Treatment Market to Surpass US$ 20,595.6 Million by 2030, Says Coherent Market Insights (CMI)

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions